

24 November 2020

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Launch of new private sector testing service

Novacyt, an international specialist in clinical diagnostics, announces the launch of a new service, known as VersaLab™, to support private sector testing of infectious diseases, initially focused on COVID-19.

Novacyt's market leading position in COVID-19 polymerase chain reaction (PCR) testing has resulted in an increased customer base and an enhanced reputation for innovation and high performance of its products, enabling the Company to forge strong relationships with accredited testing laboratories and specialist private healthcare providers. VersaLab™ combines the expert technical and commercial know-how of this network, with Novacyt's COVID-19 product portfolio and market intelligence, to offer private companies bespoke testing solutions.

The VersaLab™ service includes varying levels of PCR testing, depending on the customer's requirements, to diagnose the presence of an active COVID-19 infection. The service also includes antibody testing to show previous infections of COVID-19.

- **On-site COVID-19 testing using Novacyt's rapid PCR q16 and q32 platforms.** For customers needing results quickly, with the ability to run laboratory testing on-site, Novacyt can provide its portable q16 and q32 instruments for use alongside the Company's PCR tests, designed to deliver an accurate result within an hour. Training is also provided.
- **Centrally managed COVID-19 PCR testing using a network of private laboratories across the UK, US and planned expansion in Europe.** Using an extensive network of laboratories and Novacyt's PCR tests, VersaLab™ can support COVID-19 testing. Sample collection can be managed either by the customers' own staff, following training from VersaLab™, or external, trained personnel, with the samples sent via post.
- **Fully managed on-site COVID-19 PCR testing.** VersaLab™ can deploy complete testing and processing capacity on-site to meet a customer's needs, which includes the supply of Novacyt's PCR tests, trained personnel to manage sample collection and an operational mobile laboratory.
- **Centrally managed COVID-19 antibody testing using a network of private laboratories across the UK, US and planned expansion in Europe.** Using an extensive network of laboratories and Novacyt's ELISA IgG tests, VersaLab™ can support testing for the prevalence of COVID-19 antibodies. Sample collection can be managed either by the customers' own staff, following training from VersaLab™, or external, trained personnel, with the samples sent via post.

Ian Sanders, Sales Director Private Healthcare, Novacyt, commented:

"VersaLab™ aims to make COVID-19 testing easy and accessible for private companies. In addition, with the UK Department of Health and Social Care recently publishing new

guidance on standards for private sector testing, VersaLab™ offers customers access to reliable and accredited services to support their testing requirements. This service leverages our enhanced reputation, market intelligence and relationships developed during our response to COVID-19 to continue to address needs in the diagnostics market.”

Novacyt continues to support health authorities in the UK and globally through its reliable COVID-19 PCR testing portfolio as part of national strategies to mitigate the health and economic consequences of the pandemic.

Contacts

Novacyt SA

Ian Sanders, Sales Director Private Healthcare, Novacyt
Ian.sanders@novacyt.com

Primerdesign Customer Care team

enquiry@primerdesign.co.uk
+44 (0)2380 748 830

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com